+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06249347

Comparing Pulmonary Vein Isolation with Additional Left Atrium Linear Ablations and Left Atrial Appendage Closure in Treating Non-Paroxysmal Atrial Fibrillation

Led by Second Affiliated Hospital of Wenzhou Medical University · Updated on 2024-02-12

166

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new treatment approach called the PROMISED procedure for patients with non-paroxysmal atrial fibrillation AF. This study compares this new strategy, which includes circumferential pulmonary vein isolation PVI, left roof linear, mitral isthmus linear, and left anterior septal linear ablation combined with left atrial appendage LAA device occlusion, against the standard PVI combined with LAA closure. The goal is to determine if the PROMISED procedure improves the long-term success rate of catheter ablation in these patients by modifying the atrial substrate involved in AF initiation and maintenance, while addressing stroke risk with LAA occlusion. Participants are randomly assigned to one of two groups. One group receives the PROMISED procedure involving PVI, three types of linear ablations, and LAA device closure. The other group undergoes PVI with LAA closure only. Procedures involve the use of a radiofrequency ablation catheter guided by a circular mapping catheter and LAA angiography to select the appropriate occlusion device. Ablation is stopped if sinus rhythm is restored early. The treatment is delivered in a single procedure session for each participant. During the study, participants are monitored for recurrence of atrial arrhythmias, including atrial fibrillation, flutter, and tachycardia, for 12 months after the procedure. Researchers will also observe procedural complications, rhythm conversions during ablation, and device-related events such as thrombus or leaks at 3 months. Anticoagulant use is tracked at 6 months post-procedure. The study includes detailed procedural timing measurements and safety evaluations from hospital discharge through one year, with a total participation duration of at least 12 months after the initial ablation.

CONDITIONS

Brief Title

Left Roof Linear, Mitral Isthmus Linear and Left Anterior Septal Linear Ablation for Non-paroxysmal AF: PROMISED Trial.

Research Team

Y

Yue-chun Li, MD

Y

Yuan-nan Lin, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here